Biotechnology Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline – Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI) Read more
Cannabis Congress Discusses Remaining FY2024 Spending Bill With Provisions On Cannabis Sales And Psychedelic Clinical Trials Read more
Cannabis US Police Seizures Of Psychedelic Mushrooms Increased In Recent Years, New Study Finds Read more